Valneva SE

What they do

Valneva develops and commercializes prophylactic vaccines for infectious diseases. Its portfolio includes IXIARO (Japanese encephalitis), DUKORAL (cholera), and IXCHIQ, the first licensed chikungunya vaccine. The company also provides third-party manufacturing and R&D services.

Revenue drivers

• IXIARO — Sold mainly to U.S. military and travelers; a core commercial product with recurring procurement revenue.
• DUKORAL — Oral cholera vaccine sold primarily in Europe and other international markets; contributes steady product sales.
• IXCHIQ (chikungunya vaccine) — Partnered with Serum Institute of India for supply and sales; launched in the U.S. and contributes royalty and commercial revenue.
• Third-party products and services — Includes manufacturing for other vaccine companies and R&D support; diversifies revenue beyond proprietary vaccines.

Recent performance

In 2025, total product sales were EUR 123.1 million, up 23% from EUR 100.1 million in 2024. IXIARO and DUKORAL remained the primary revenue contributors, while IXCHIQ sales grew following its U.S. launch. R&D and service revenue declined as COVID-19 programs wound down, and milestone and licensing revenue decreased. The company reported a net loss in 2025, in part due to higher R&D spending on late-stage candidates.

Strategy

Valneva is prioritizing the commercial expansion of IXCHIQ, supported by the partnership with Serum Institute of India. It is advancing a Phase 3 Lyme disease vaccine (VLA15) with Pfizer, which could be a major growth driver. Management also aims to grow IXIARO and DUKORAL through market expansion and new supply contracts. The company is investing in manufacturing capacity and geographic diversification to support this pipeline.

Risks

• Reliance on IXIARO and DUKORAL — Significant sales concentration in two legacy vaccines; any supply disruption or demand decline would hit revenue.
• Clinical and regulatory uncertainty for VLA15 — The Lyme vaccine is a high-value program but faces Phase 3 trial and regulatory approval risks.
• IXCHIQ market adoption risk — Chikungunya vaccine demand depends on outbreak patterns and public health prioritization, which are unpredictable.
• Liquidity and debt obligations — The company has debt due in 2028 and 2030 and must manage liquidity to fund R&D without excessive dilution.

Outlook

Management expects product sales to continue growing in 2026, driven by IXCHIQ and IXIARO. VLA15 Phase 3 readouts are a key near-term catalyst, with potential BLA submission if successful. The company also anticipates expanding DUKORAL availability in new markets.